Healthcare

On 29 October 2026, the rare-disease drug developer reported third-quarter revenue of US$353.2 million, close to three times the prior-year level, driven by Attruby (acoramidis), its treatment for transthyretin amyloid cardiomyopathy (ATTR-CM). The company also reiterated a 27 November 2026 FDA target action date …

The late-breaking oral presentation came two days after the company highlighted long-term and dosing data for BRIUMVI, its marketed anti-CD20 antibody for relapsing MS.

The Minnesota-based company said it has not identified any material impact on its financial condition or results so far, including expected legal and advisory costs.

Key HighlightsRegeneron Pharmaceuticals (NASDAQ:REGN) climbed about 13 percent on October 30, 2026 after third-quarterRevenuegrew 36 percent, with one published report showing a 12.5 percent rise in mid-morning trading and a 13.3 percent rise at the close.Stryker (NYSE:SYK) dropped about 10 percent after its chief …

The REMS question traces to thalassemia. In those trials, 5 of 301 patients had liver injury, 2 of them serious. Mitapivat has been sold for thalassemia under theBrandAQVESME since late January, only under a REMS, according to published coverage. Agios reports no sickle cell …

The weak spot was joint replacement. Hip sales dipped 1 percent while knee sales rose 1.1 percent, whereas Johnson & Johnson (NYSE:JNJ) reported knee growth of 2.5 percent and hip growth of 3.2 percent in the same period, according to published coverage. Lobo said …

The medical benefits ratio compares medical costs with premiums, so a 240 basis point rise means a larger share of each premium dollar went to care. The company cited Part D seasonality, the timing of clinical investments, elevated appeals and disputes, and higher costs …